干细胞之家 - 中国干细胞行业门户第一站

 

 

搜索
朗日生物

免疫细胞治疗专区

欢迎关注干细胞微信公众号

  
查看: 5640|回复: 1
go

[已解决求助] 求助Virology. 2011 文献 [复制链接]

Rank: 3Rank: 3

积分
318 
威望
318  
包包
7  

优秀会员

楼主
发表于 2011-3-25 20:07 |只看该作者 |倒序浏览 |打印
Virology. 2011 Jan 5;409(1):113-20. Epub 2010 Oct 28.+ D9 ^- y& x8 {$ @& x0 B% ?" y: Q

# J$ p; ]  Y; p5 e' R# N- W/ E7 T# sHuman Trim5α has additional activities that are uncoupled from retroviral capsid recognition.) G% I$ D- _. P6 v( ]
Tareen SU, Emerman M.! c5 f3 d5 A5 ^0 c& ~

  ?7 }; {1 R" T/ CMolecular and Cellular Biology Program, University of Washington, Seattle, WA 98195, USA.9 q# d. ]0 C3 c! L

  B# V2 g. d8 f: Q& ^6 q! X: LAbstract9 s" z$ J( }5 S
Trim5α is a host antiviral protein that recognizes incoming retroviral capsids in the cytoplasm and prevents productive infections. Although present in most mammals, the state of the Trim5 gene is dynamic in that primates have one copy with several splice variants, while rodents and cows have multiple copies. Mouse Trim30 (one of the mouse Trim5α homologs) has been shown to negatively regulate NF-kappaB activation by targeting upstream signaling intermediates TAB2 and TAB3 for degradation. We show that human Trim5α also affects levels of TAB2, resulting in abrogation of TAB2-dependent NF-kappaB activation. Surprisingly, unlike mouse Trim30, human and rhesus Trim5α are able to activate NF-kappaB-driven reporter gene expression in a dose-dependent manner. We show that Trim5α uses distinct domains for the distinct abilities of affecting TAB2 levels, regulating NF-kappaB, and recognizing retroviral capsids. Our results demonstrate functions of Trim5α that are not dependent on recognizing the retroviral capsid.( Z. Z: [" V* P/ l, ~4 ^

/ O0 O% z) d& a9 O7 d

Rank: 2

积分
120 
威望
120  
包包
1443  
沙发
发表于 2011-3-25 21:36 |只看该作者
附件: 你需要登录才可以下载或查看附件。没有帐号?注册
已有 1 人评分威望 包包 收起 理由
细胞海洋 + 2 + 5 欢迎参与文献互助

总评分: 威望 + 2  包包 + 5   查看全部评分

‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册
验证问答 换一个

Archiver|干细胞之家 ( 吉ICP备2021004615号-3 )

GMT+8, 2024-11-1 07:45

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.